Announcements Trials
Browse Landscape

Phase

Phase 2 50Phase 1 30Phase 1/2 14Phase 3 9Phase NA 5Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 7Glioma 6Brain Neoplasms 3Neuroblastoma 2Sarcoma 1Rhabdoid Tumor 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Pinealoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Medulloblastoma 1Gliosarcoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

motexafin gadolinium 1irinotecan sucrosofate 1bemcentinib 1Vincristine 1Temozolomide 1Rituximab 1Radiotherapy 1Radiation 1Procarbazine 1Postoperative Period 1Pemetrexed 1Nivolumab 1Methotrexate 1Memantine 1Irinotecan 1Immunotherapy 1Donepezil 1Cytarabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Central Nervous System Neoplasms × Temozolomide × Clear all
NCT03554707 2026-05-08

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

SynerGene Therapeutics, Inc.

Phase EARLY_PHASE1 Withdrawn
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡